(TNND) — The Food and Drug Administration (FDA) is set to integrate Artificial Intelligence (AI) into its decision-making processes, aiming to enhance the speed and efficiency of evaluating drugs, foods, medical devices, and diagnostic testing. According to Axios, the agency plans to incorporate generative AI as part of its strategy to become faster and leaner.
A pilot program has already been conducted, and the FDA intends to have AI work alongside employees to expedite the evaluation process. Commissioner Marty Makary announced that the new process is expected to be implemented by June 30.
Makary said, “The technology could slash tasks in the review process for new therapies from ‘days to just minutes.’”
Concerns have been raised regarding the security of proprietary data involved in the process. Jeremy Walsh, formerly of Booz Allen Hamilton, has been appointed as the Chief AI Officer to lead this initiative.
Elon Musk has been a prominent advocate for an AI-first strategy in government. Other government agencies are also exploring AI applications, with the General Services Administration utilizing an AI chatbot and the Social Security Administration planning to use AI for transcribing applicant hearings.
发表回复